Earlier this month Saluda Medical, a global medical device company developing in the field of neuromodulation, announced $125M in equity funding. Throughout the last decade, Saluda has evolved innovations designed to read, record, and respond to the nervous system during stimulation. The technology is able to provide dosing that can be titrated at the microsecond
Saluda Medical Enters The Market With FDA Approval
